drugset / Trial / NCT00499473
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2007-06
- Primary completion
- 2009-06
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | — | Oral |